Recombinant
RabMAb

Anti-VEGFD antibody [EPR8457] (ab155288)

Overview

  • Product name
    Anti-VEGFD antibody [EPR8457]
    See all VEGFD primary antibodies
  • Description
    Rabbit monoclonal [EPR8457] to VEGFD
  • Host species
    Rabbit
  • Tested applications
    Suitable for: WB, IHC-P, Flow Cyt, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human VEGFD. The exact sequence is proprietary.
    Database link: O43915
    (Peptide available as ab189506)

  • Positive control
    • Raji, HT-1080, MCF-7, and Caco-2 cell lysates. Human heart and lung tissue.
  • General notes

    A trial size is available to purchase for this antibody.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab155288 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 40 kDa.
IHC-P 1/100 - 1/700.
Flow Cyt 1/100 - 1/500.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

ICC/IF 1/200.

Target

  • Function
    Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
  • Tissue specificity
    Highly expressed in lung, heart, small intestine and fetal lung, and at lower levels in skeletal muscle, colon, and pancreas.
  • Sequence similarities
    Belongs to the PDGF/VEGF growth factor family.
  • Post-translational
    modifications
    Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3 and VEGFR-2. VEGF-D first form an antiparallel homodimer linked by disulfide bonds before secretion. The fully processed VEGF-D is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • c-fos induced growth factor antibody
    • c-fos induced growth factor (vascular endothelial growth factor D) antibody
    • c-fos induced growth factor antibody
    • c-fos-induced growth factor antibody
    • FIGF antibody
    • Vascular endothelial growth factor D antibody
    • Vascular endothelial growth factor D precursor antibody
    • Vascular endothelial growth factor D precursor antibody
    • VEGF D antibody
    • VEGF-D antibody
    • VEGFD antibody
    • VEGFD_HUMAN antibody
    see all

Images

  • ab155288 staining VEGFD in MCF-7 (human breast carcinoma) cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody at a dilution of 1/200. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody. ab7291 and ab150120 were used as counterstains for primary antibody ab155288 and secondary antibody ab150077 respectively and DAPI was used as a nuclear counterstain.

    Negative control 1: Rabbit primary antibody and anti-mouse secondary antibody (ab150120)
    Negative control 2: Mouse primary antibody (ab7291) and anti-rabbit secondary antibody (ab150077)

  • All lanes : Anti-VEGFD antibody [EPR8457] (ab155288) at 1/10000 dilution

    Lane 1 : Raji (human Burkitt's lymphoma) whole cell lysate
    Lane 2 : HT1080 (human fibrosarcoma) whole cell lysate
    Lane 3 : Caco-2 (human colorectal adenocarcinoma) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 40 kDa
    Additional bands at: 40 kDa. We are unsure as to the identity of these extra bands.



    Diluting and blocking buffer: 5% NFDM/TBST

  • ab155288 staining VEGFD in the human cell line NIH/3T3 (mouse embryo) by flow cytometry. Cells were fixed with 4% paraformaldehyde and the sample was incubated with the primary antibody at a dilution of 1/200. A goat anti rabbit IgG (Alexa Fluor® 488) at a dilution of 1/2000 was used as the secondary antibody.

    Isoytype control: Rabbit monoclonal IgG (Black)

    Unlabelled control: Cell without incubation with primary antibody and secondary antibody (Blue)

  • ab155288 staining VEGFD in human cardiac muscle tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with paraformaldehyde and antigen retrieval was by heat mediation in a EDTA buffer. Samples were incubated with primary antibody at a dilution of 1/700. A goat anti-rabbit IgG H&L (HRP) ab97051 was used as the secondary antibody at a dilution of 1/500.

    Negative control: PBS in place of primary antibody.

  • All lanes : Anti-VEGFD antibody [EPR8457] (ab155288) at 1/2000 dilution

    Lane 1 : Rat lung tissue lysate
    Lane 2 : NIH/3T3 (mouse embryo) whole cell lysate

    Lysates/proteins at 15 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

    Predicted band size: 40 kDa
    Additional bands at: 40 kDa. We are unsure as to the identity of these extra bands.



    Diluting and blocking buffer: 5% NFDM/TBST

  • All lanes : Anti-VEGFD antibody [EPR8457] (ab155288) at 1/1000 dilution

    Lane 1 : Raji lysate
    Lane 2 : HT-1080 lysate
    Lane 3 : MCF-7 lysate
    Lane 4 : Caco-2 lysate

    Lysates/proteins at 10 µg per lane.

    Predicted band size: 40 kDa

  • Immunohistochemical analysis of paraffin embedded Human heart tissue labeling VEGFD with ab155288 at a 1/100 dilution.
  • Immunohistochemical analysis of paraffin embedded Human lung tissue labeling VEGFD with ab155288 at a 1/100 dilution.
  • Immunohistochemical analysis of paraffin embedded Human normal kidney tissue using ab155288 showing +ve staining.

  • Immunohistochemical analysis of paraffin embedded Human skeletal muscle tissue using ab155288showing +ve staining.

References

This product has been referenced in:
  • Zhao T  et al. The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells. Exp Ther Med 15:4370-4378 (2018). Read more (PubMed: 29725377) »
  • Hong H  et al. TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. BMC Cancer 16:240 (2016). IHC . Read more (PubMed: 26992854) »

See all 2 Publications for this product

Customer reviews and Q&As

Ab155288 has not been tested specifically for cross-reactivity with VEGFC, however I aligned the immunogen sequence against the human VEGFC sequence and there is no significant similarity between the sequences. So, we would not predict the antibody to ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up